Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC).

“We look forward to reporting results in the third quarter of this year, and to advancing ADL5945 into pivotal testing in the first quarter of 2012. OIC is a frequent and serious consequence of long-term opioid-based pain management and an effective treatment for this condition remains an unmet medical need.”

Adolor is conducting two Phase 2 studies of ADL5945 in OIC patients in parallel. The first study is evaluating two doses of ADL5945 - 0.10 mg and 0.25 mg - given twice daily versus placebo over a 4-week, double-blind treatment period. The second study, of similar design, is evaluating 0.25 mg of ADL5945 given once daily versus placebo. The trials have enrolled 40 or more patients in each arm, for a combined total of over 200 patients.

"Enrollment has progressed quite well in these studies," said Michael R. Dougherty, President and Chief Executive Officer. "We look forward to reporting results in the third quarter of this year, and to advancing ADL5945 into pivotal testing in the first quarter of 2012. OIC is a frequent and serious consequence of long-term opioid-based pain management and an effective treatment for this condition remains an unmet medical need."